Pharming meldt acceptatie voor beoordeling door FDA van verzoek tot aanvullende profylaxe-licentie voor RUCONEST®

FDA publiceert besluit op 21 september 2018 Leiden, 17 January 2018: Pharming Group NV ("Pharming" of "de Onderneming") (Euronext Amsterdam: [...]

Pharming announces FDA Acceptance for Review of Supplemental Biologics License Application for RUCONEST® for Prophylaxis of Hereditary Angioedema Attacks

Leiden, The Netherlands, 17 January 2018: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) announced today that the [...]


7mar07:00Full Year Results


17may07:00First Quarter Results (1Q)


26jul07:00Half Year Results (1H)